Skip to main content

Advertisement

SpringerLink
Log in

Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s. Although several studies have been conducted, the results remain controversial. Randomized controlled trials have an improved balance of confounding factors and reliable results. Thus, we performed a meta-analysis based on randomized controlled trials to gather more evidence of the effect of ifosfamide on neoadjuvant chemotherapy for patients with osteosarcoma of the extremity. An electronic search was conducted via the Internet retrieval system to identify eligible trials until September 2014. Odds ratios (ORs) and 95 % confidence interval (CI) were calculated to compare the results of ifosfamide and ifosfamide-free therapies. Four trials with a total of 1,378 patients were eligible for our meta-analysis. Overall, compared with neoadjuvant chemotherapy without ifosfamide, the use of ifosfamide had no advantage in terms of histological response to chemotherapy (cHR; OR 1.36; 95 % CI 0.90–2.03, P = 0.140), 5-year event-free survival (EFS; OR 1.16; 95 % CI 0.789–1.75, P = 0.464), and 5-year overall survival (OS; OR 1.06; 95 % CI 0.70–1.59, P = 0.794). However, improvement was noted in the rate of limb salvage (OR 4.06; 95 % CI 2.04–8.10, P < 0.001). Neoadjuvant chemotherapy with ifosfamide for patients with extremity osteosarcoma might not increase the cHR and exhibited no significant effect on either EFS or OS. However, ifosfamide therapy could significantly increase the rate of limb salvage for osteosarcoma of the extremity, which suggests that the preoperative use of ifosfamide could increase the success rate of limb salvage operation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670–8.

    Article  PubMed  Google Scholar 

  2. van Dalen EC, van As JW, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev. 2011;5:CD006325.

    PubMed  Google Scholar 

  3. Smelangd S, et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma. Acta Orthop. 2011;82:211–6.

    Article  Google Scholar 

  4. Bacci G, et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group Pilot Study. J Chemother. 2002;14:198–206.

    Article  CAS  PubMed  Google Scholar 

  5. Le Deley MC, et al. SFOP OS94: a randomized trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752–61.

    Article  PubMed  Google Scholar 

  6. Bacci G, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98–104.

    Article  CAS  PubMed  Google Scholar 

  7. Ferrari S, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30:2112–8.

    Article  CAS  PubMed  Google Scholar 

  8. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic review and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.

    Article  PubMed  Google Scholar 

  9. Maxwell L, et al. Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol. 2006;33:2304–11.

    PubMed  Google Scholar 

  10. Wells GA, et al. The Newcastle-Ottawa Scala (NOS) for assessing the quality of nonrandomized studies in meta-analyses, Ottawa Health Research Institute Web site. 2012.

  11. Deeks J, Higgins JPT. Analysis data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions 5.0.0. http://www.cochrane-handbook.org). Accessed 15 July 2011.

  12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Mantel N, Haenszel E. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    CAS  PubMed  Google Scholar 

  14. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Meyer PA, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–11.

    Article  Google Scholar 

  16. Hong S, et al. Comparison of long-term outcome between doublet and triblet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. Oncology. 2011;80:107–17.

    Article  CAS  PubMed  Google Scholar 

  17. Whelan JS, et al. Survival from high-grade localized extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomized controlled trials. Ann Oncol. 2012;23:1607–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Marti C, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115–7.

    CAS  PubMed  Google Scholar 

  19. Pratt CB, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131–5.

    CAS  PubMed  Google Scholar 

  20. Bacci G, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Instituto Ortopedico Rizzoli according to the Instituto Ortopedico/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–27.

    CAS  PubMed  Google Scholar 

  21. Lin F, et al. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7:270–5.

    Article  CAS  PubMed  Google Scholar 

  22. Kudawara I, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother. 2013;25:41–8.

    Article  CAS  PubMed  Google Scholar 

  23. Bacci G, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004;90:478–84.

    PubMed  Google Scholar 

  24. Bacci G, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at single institution. Cancer. 2006;106:1154–61.

    Article  PubMed  Google Scholar 

  25. Durnali A, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.

    Article  PubMed  Google Scholar 

  26. Smeland S, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488–94.

    Article  CAS  PubMed  Google Scholar 

  27. Goorin AM, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–80.

    Article  CAS  PubMed  Google Scholar 

  28. Yin K, et al. Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture. Exp Ther Med. 2012;4:889–94.

    PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Oncology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, 524001, Guangdong, China

    Wenmei Su, Zhennan Lai, Yanming Lin, Yanli Mo & Zhixiong Yang

  2. Department of Radiotherapy, The Tumor Hospital of Chengdu, The Seventh People’s Hospital of Chengdu, Chengdu, 610041, Sichuan, China

    Fenping Wu

  3. Nutritional Department, Affiliated Hospital of Guangdong Medical College, Zhanjiang, 524001, Guangdong, China

    Jiayuan Wu

Authors
  1. Wenmei Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhennan Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fenping Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanming Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanli Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhixiong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiayuan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiayuan Wu.

Additional information

Zhixiong Yang and Jiayuan Wu have equally contributed to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

12032_2014_481_MOESM1_ESM.tif

Effects of individual studies on pooled odds ratios (ORs) for neoadjuvant chemotherapy with or without ifosfamide in extremity osteosarcoma. (A) Sensitivity analysis for the outcome of cHR. (B) Sensitivity analysis for the outcome of 5-year EFS. (C) Sensitivity analysis for the outcome of 5-year OS. (D) Sensitivity analysis for the outcome of limb salvage rate. (TIFF 683 kb)

12032_2014_481_MOESM2_ESM.tif

Funnel plot for neoadjuvant chemotherapy with or without ifosfamide in extremity osteosarcoma. (A) Funnel plot to assess the cHR. (B) Funnel plot to assess the 5-year EFS. (C) Funnel plot to assess the 5-year OS. (D) Funnel plot to assess the limb salvage rate. (TIFF 807 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Su, W., Lai, Z., Wu, F. et al. Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. Med Oncol 32, 19 (2015). https://doi.org/10.1007/s12032-014-0481-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0481-y

Keywords

Search

Navigation